Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announced that its CEO and Chairman, John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled to take place from Sept. 14-16, 2026, at the Lotte New York Palace Hotel. This presentation provides an opportunity for the company to showcase its innovative approach to oncology therapeutics to a broad audience of investors and industry professionals.
The significance of this presentation lies in the growing need for treatments that address drug resistance, a major challenge in cancer therapy. Many patients initially respond to standard treatments but later experience relapse due to resistance mechanisms. Kairos Pharma is leveraging structural biology to tackle this issue head-on. Its lead candidate, ENV-105, is an antibody that targets CD105, a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. This mechanism has the potential to significantly improve patient outcomes and represents a promising avenue in the fight against cancer.
The conference presentation is a key platform for Kairos Pharma to communicate its scientific rationale, clinical development plans, and the potential impact of ENV-105. It also signals the company's commitment to advancing its pipeline and engaging with the investment community. For investors, this is an opportunity to gain insights into the company's strategy and the progress of its lead candidate. The announcement follows the company's ongoing efforts to establish itself as a leader in overcoming drug resistance, a niche area with substantial unmet medical need.
In addition to the presentation, interested parties can access the full press release and more information about Kairos Pharma through the company's newsroom at this link and here. The company is based in Los Angeles, California, and is dedicated to developing therapies that could change the standard of care for cancer patients.
